RET Breakapart

Clinic Significance:
1.This occurs in 1-2% of patients with non-small cell lung adenocarcinoma
2.The expression was lower in normal lung tissue, and the gene rearrangement activated the kinase active domain of RET, and the expression was higher in lung cancer samples.
Three targeted drugs, Vandetanib, Sorafenib and Sunitinib, inhibit the activity of multiple receptor tyrosine kinases including RET, and to kill cells carrying RET fusion gene.


RET Normal

RET Breakapart

More Info

Probe Description: RET

Cat.No.: CF1019

Specification: 10 tests/box, 20 tests/box

Related Product

Get in touch

If you have an inquiry or some feedback for us ,please fill out the form below to contact our team.